| Field | Specification |
|---|---|
| Target | |
| Alternative names | Lignocaine hydrochloride |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C14H23ClN2O |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Lidocaine hydrochloride, also known as Lignocaine hydrochloride, inhibits sodium channels through complex voltage- and use-dependence[1]. It decreases growth, migration and invasion of gastric carcinoma cells by up-regulating miR-145 expression and thereby inactivating the MEK/ERK and NF-κB signaling pathways. As an amide derivative, it is described as an agent for treating ventricular arrhythmia and an effective tumor inhibitor[2]. It is supplied as a white to off-white solid (C14H23ClN2O, MW 270.80) at 99.84% purity.
Physical & Chemical Properties
| CAS Number | 73-78-9 |
|---|---|
| Molecular Formula | C14H23ClN2O |
| Molecular Weight | 270.80 g/mol |
| Purity | 99.84% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=C(NC1=C(C)C=CC=C1C)CN(CC)CC.[H]Cl |
| Target | MEK, ERK, NF-κB |
| Signaling Pathway | Membrane Transporter/Ion Channel; MAPK/ERK Pathway; Stem Cell/Wnt; NF-κB; Apoptosis |
| Solubility | In Vitro: H2O: ≥ 100 mg/mL (369.28 mM) DMSO: ≥ 100 mg/mL (369.28 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) * "≥" means soluble, but saturation unknown. |
| Storage | 4°C, sealed storage, away from moisture and light. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| H2O | ≥ 100 mg/mL (369.28 mM) | — |
| DMSO | ≥ 100 mg/mL (369.28 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture and light; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (9.23 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.5 mg/mL (9.23 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (9.23 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Direct preparation of the working solution
These formulations are prepared directly, without a DMSO stock; use them promptly after preparation.
Protocol 4
| Composition | PBS |
|---|---|
| Result | 120 mg/mL (443.13 mM); clear solution; requires sonication |
Data provided by the manufacturer.
In Vitro
Lidocaine hydrochloride (Lignocaine hydrochloride) (10 nM; 48 hours) significantly decreases cell proliferation[2]. Lidocaine hydrochloride (1-10 nM; 24-72 hours) suppresses cell viability, with the strongest effect at 10 nM and a treatment time of 48 hours[2]. Lidocaine hydrochloride (10 nM; 48 hours) significantly raises the apoptotic cell rate[2]. Lidocaine hydrochloride (10 nM; 48 hours) significantly down-regulates Cyclin D1 and up-regulates p21 expression[2].
Cell Proliferation Assay[2]
| Cell Line | The human gastric cancer cell line MKN45 |
|---|---|
| Concentration | 10 nM |
| Incubation Time | 48 hours |
| Result | Decreased significantly cell proliferation. |
Cell Viability Assay[2]
| Cell Line | The human gastric cancer cell line MKN45 |
|---|---|
| Concentration | 1, 5 and 10 nM |
| Incubation Time | 24, 48, 72 hours |
| Result | Inhibited MKN45 cell viability. |
Apoptosis Analysis[2]
| Cell Line | The human gastric cancer cell line MKN45 |
|---|---|
| Concentration | 10 nM |
| Incubation Time | 48 hours |
| Result | Increased significantly the apoptotic cell rate. |
Western Blot Analysis[2]
| Cell Line | The human gastric cancer cell line MKN45 |
|---|---|
| Concentration | 10 nM |
| Incubation Time | 48 hours |
| Result | Down-regulated Cyclin D1 and up-regulated p21 expression significantly. |
In Vivo
In rats, Lidocaine hydrochloride (Lignocaine hydrochloride) produces a fully reversible tail nerve block. Compared with thermal nociception block, the mechanical nociception block from lidocaine has a slower onset and faster recovery[3].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Metabolomic profiling of single enlarged lysosomes. Nat Methods 2021 Jul;18(7):788-798. PMID: 34127857
Molecular determinant of low-voltage dependence of human Nav1.7 inactivation revealed by efficacy-based Nav1.7 selective inhibitor. Nat Commun 2026 Feb 10;17(1):2559. PMID: 41667447
A worm-like nucleic acid nanostructure for gene delivery and endosomal escape via ClC3 ion exchanger. Sci Adv 2026 Mar 6;12(10):eadw0891. PMID: 41790895
EphB1-NR2B receptor signaling in glutamatergic neurons of the ventroposteromedial thalamic nucleus regulates emergence from anesthesia. Sci Adv 2025 Dec 5;11(49):eadw7972. PMID: 41348875
Lidocaine alleviates morphine tolerance via AMPK-SOCS3-dependent neuroinflammation suppression in the spinal cord. J Neuroinflammation 2017 Nov 2;14(1):211.
Local anesthetics impair the growth and self-renewal of glioblastoma stem cells by inhibiting ZDHHC15-mediated GP130 palmitoylation. Stem Cell Res Ther 2021 Feb 4;12(1):107. PMID: 33541421
Stellate ganglion block diminishes consolidation of conditioned fear memory in mice by inhibiting the locus coeruleus to the basolateral amygdala neural circuit. Transl Psychiatry 2025 May 17;15(1):172. PMID: 40382311
Traditional Chinese Medicine YangxinDingji alleviates arrhythmias through inhibition of sodium and L-type calcium channels. J Ethnopharmacol 2025 May 12:347:119803. PMID: 40239882
Hydrogel-based drug delivery system designed for chemotherapy-induced alopecia. Biomater Adv 2026 Jan:178:214452. PMID: 40876091
Dexmedetomidine Prolongs Lidocaine Intravenous Regional Anesthesia in Rats by Blocking the Hyperpolarization-Activated Cation Current. Drug Des Devel Ther 2024 Apr 9:18:1103-1114. PMID: 38618283
